The head of the pharmaceutical company Pfizer, Albert Bourla, may expect a new vaccine by the fall that protects against both the ommicron variant and other variants of the corona virus. “It’s easy to do something alone against Omikron,” he explained at an event of the international pharmaceutical association IFPMA on Wednesday.
It is scientifically and technically more demanding to develop an effective vaccine against all known variants of the pathogen SARS-CoV-2. He hopes that such a vaccine will be available in the fall. But what the world “really needs,” Bourla said, is a vaccine that will last a year as people get tired of more boosters. “We’re working on that.”
Technically, however, developing an effective vaccine against all known variants is challenging, according to Bourla, due to the nature of the virus. According to their own statements, Biontech and Pfizer started developing a vaccine against Covid-19 tailored to the Omicron variant at the end of November 2021. According to the two companies, the mRNA-based serum has been pre-manufactured “at risk” for some time.
In mid-February, Biontech founder Ugur Sahin announced that delivery of the vaccine tailored to the Omicron variant would begin in April or May. The modified vaccine was originally announced for March. In January, Biontech and Pfizer projected a production capacity of up to four billion vaccine doses worldwide for this year.
Source: Krone
I’m Wayne Wickman, a professional journalist and author for Today Times Live. My specialty is covering global news and current events, offering readers a unique perspective on the world’s most pressing issues. I’m passionate about storytelling and helping people stay informed on the goings-on of our planet.
